Analytical error of home glucose monitors: a comparison of 18 systems
|
|
- Beatrice Wilson
- 6 years ago
- Views:
Transcription
1 Original Article Ann Clin Biochem 1999; 36: Analytical error of home glucose monitors: a comparison of 18 systems Roger N Johnson and John R Baker From the Department of Clinical Biochemistry, Green Lane and the National Women's Hospitals, Auckland, New Zealand SUMMARY. In a quality review of 18 home blood glucose monitors, we measured the imprecision and incidence of significant error of 12 colorimetric and six amperometric systems by using capillary blood specimens from patients attending diabetes clinics. Imprecision at the mean glucose concentration found in the respective blood specimens (about 9 mmol/l) gave coefficients of variation (CV) ranging from 5 2 to 22 8%. Eight monitors including five of amperometric design had a CV of less than 10%. The incidence of significant error (defined as the proportion of specimens differing in value by more than 15% from a reference hexokinase assay of glucose in capillary blood) varied from 6 to 76%. Among the eight monitors identified as being most precise, the majority produced results that differed markedly from the reference assay, underlining the need for a common approach to calibration of home glucose monitors. Additional key phrases: blood glucose self-monitoring; blood glucose analysis In recognition of the importance of selfmonitoring of blood glucose (SMBG) to the management of diabetes mellitus, the American Diabetes Association and other expert groups (collectively abbreviated ADA) met in 1986 to reach a consensus view on its application and performance.' They proposed analytical goals for devices used for 5MBG, namely 'a variability (system plus user) of < 10% at glucose concentrations of 3{}-400mg/dL ( mmol/L) 100% of the time', and 'with current systems, 5MBG measurements should be within 15% of the results of the reference method'. Later, at a second conference in 1993, they recommended tightening the limits on 'analytic error' to within 5%.2 This more stringent guideline came at the same time as the clear benefits of tight control of blood glucose concentration were shown by the Diabetes Control and Complications Trial.' Correspondence: Dr R N Johnson, Department of Clinical Biochemistry, National Women's Hospital, Private Bag 92\89, Auckland 3, New Zealand. nwbiochem@ahsl.co.nz Whether monitors are able to match these recommended performance standards is uncertain. Earlier surveys such as those by Koschinsky et al. in and Havlin et al. in 199)5 did not find any monitors that reached the ADA goals of Since that time, manufacturers have made monitors easier to use and less dependent on the skill of the operator, but whether those currently available are better able to meet the guidelines remains in doubt. In a previous paper.f we described a wide variation in inaccuracy or calibration bias in 17 different monitoring products, and commented on the difficulties that this factor alone may cause in the interpretation of results and the consequent management of diabetes. In the present paper, we describe measurements of imprecision and the incidence of significant error in many of these same 17 systems. We compare our findings with the recommendations made by ADA,l and discuss where the state of the art stands in relation to these putative analytical goals of a decade ago. We comment on the difficulty of applying the ADA guidelines in practice and re-emphasize the need for a common basis for calibration and reporting, 72
2 Analytical error ofhome glucose monitors 73 either as a concentration of glucose in whole blood or in plasma. PATIENTS AND METHODS The study was approved as a clinical audit by the Ethics Committee of the Northern Regional Health Authority of New Zealand. As described in detail previously," patients attending two diabetes clinics were invited to participate. Upon their agreement, each had a single capillary blood specimen taken by one of four registered medical laboratory technologists. A portion of the blood was applied directly to the particular glucose strip under test, with the remainder collected in a fluoride micro-tube that was stored TABLE 1. Imprecision ofcolorimetric monitors Streck controls Manufacturer's controls Regression" Monitor Concentration! (n)l CV (%) Concentration! (n)l CV (%) Concentration! (n)l CV (%) One Touch 4 2 (6) (6) (51) 5 2 Profile 9 3 (6) (6) 7-6 SureStep 4 9 (8) (8) (57) (8) (8) 2-9 Accutrend 3 7 (13) (13) (76) 6 5 Alpha 9 0 (13) (13) (13) 3 5 Accutrend 3 9 (15) (15) (55) 10-4 Maxi 9 3 (15) (15) (15) 5 9 Reftolux S 4 3 (9) (9) (58) (9) (9) (9) 1.6 BM-I (10) (55) (10) (10) 14 0 Accutrend 3 9 (10) (10) (52) 12 5 Mini 9 1 (10) (10) (10) 3-8 Glucometer (10) (10) (62) (10) (10) (10) (10) 7 1 Glucometer (10) (10) (57) (10) (10) (10) (10) 5 6 Betachek 3 9 (11) (58) (11) (11) 17 2 Lynx 5 0 (10) (52) (10) (10) 16 9 Dia-Screen 4 1 (12) (52) (12) (12) 14 8 YSI ' (14) ' (16) (55) ' (14) ' (25) 1 3 CV from regression = SEE/mean [glucose] x 100%. tmean [glucose] observed (mmol/l), In = number in sample. 'Aqueous glucose solutions. YSI = the dedicated laboratory glucose analyser. Ann Clin Biochem 1999: 36
3 74 Johnson and Baker immediately at - 20 C. A rmmmum of 50 patients, representing about five clinic sessions irrespective of location, had glucose measurements made in this way with a particular monitor. The validity of the preservation technique was assessed by comparing results on the frozen capillary specimens with those from a dedicated laboratory glucose analyser (YSI 2300, Yellow Springs Instrument Co., Yellow Springs, OH, USA) used with fresh blood at one of the clinics as if it were a home glucose monitor. The monitors were also tested at each collection time with control solutions, both Sugar-Chex (Streck Laboratories, Omaha, NE, USA) from a single batch and, where available, manufacturer's controls. The monitors tested were those listed previously," with the following modifications: the Glucometer Elite (Bayer) has been superseded by the Esprit; Glucocard (Kyoto Daiichi Kagaku) by Glucocard II; and the Advantage (Boehringer-Mannheim) results reported here are solely for the newer strip based on glucose dehydrogenase (previously referred to as Universal Strip"), One Touch Profile and SureStep (both reflectance devices from Lifescan) have been made available to us since the completion of the previous report. Laboratory analysis was done after thawing the frozen blood specimens and deproteinizing them promptly with dilute perchloric acid (final concentration 0 3 mol/l), Glucose in the acid extracts was assayed with a reagent based on hexokinase and glucose-6-phosphate dehydrogenase (Boehringer-Mannheim, Mannheim, Germany) in a centrifugal analyser (Cobas Bio, Hoffman-La Roche, Basle, Switzerland). Comparison data were analysed statistically by least-squares linear regression. The results obtained by this technique did not differ from those of orthogonal regression when sample analyses were carried out with the least imprecise and most imprecise monitors. Frequency distributions were analysed by X 2 test and differences in paired data by Student's r-test, RESULTS Imprecision of measurements with glucose monitors Conventional imprecision statistics at particular concentrations of glucose were calculated after using Streck control solutions and, where provided, controls from the manufacturer of the monitor (Tables I and 2). The mean concentrations found for the Streck solutions TABLE 2. Imprecision of amperometric monitors Streck controls Manufacturer's controls Regression" Monitor Concentration" (n)1 CV (%) Concentrationt (n)1 CV (%) Concentrationt (n)1 CV (%) Glucocard II 2 6 (6) (6) (54) (6) (6) (6) 2 7 Advantage 3-4 (10) (10) (51) (10) (10) (10) 3 5 Esprit 1 8 (8) (8) (55) (8) (8) (8) (8) 1 8 Companion (14) (75) (14) (14) 5 4 Sensorex 3-8 (10) (10) (52) (10) (10) (10) 5 5 ExacTech 4 2 (10) (10) (51) (10) (10) 5 3 >25 (10) _tt *CV from regression = SEE/mean [glucose] x 100%. 'Mean [glucose] observed (mmol/l), In = number in sample. tt All measurements outside the measuring range. Ann cu«biochem 1999: 36
4 Analytical error ofhome glucose monitors 75 differed among the monitors, possibly reflecting in part disparities in accuracy' and in part a variable response to glucose presented in an unusual matrix. To the extent that comparison was possible, imprecision as judged from the Streck solutions seemed broadly similar to that obtained with the manufacturers' own controls. Imprecision of measurement of the patients' blood specimens was assessed from the dispersion of points about the line made by regressing the values from each monitor on the corresponding laboratory whole-blood glucose results. It was expressed numerically as the standard error of estimate (SEE, Sy.xy.' Coefficients of variation calculated as the SEE(mean monitor result (Sy.x(y) gave imprecision estimates that tended to be greater than those obtained with the control solutions (e.g., Streck mid-range control) at comparable mean values. Such an outcome might be anticipated because the blood specimens provided a wider range of glucose concentration than did any single control, and probably offered additional variability in such factors as viscosity, haematocrit, oxygen tension and interfering substances. In these respects the estimates of imprecision based on blood specimens more nearly represent day-to-day imprecision in actual use. Proportion of measurements with significant error The incidence of significant error in measurement was assessed after direct comparison of the result from the monitor with that from the laboratory on the corresponding capillary blood. The difference between the two values was expressed as a proportion by dividing by the laboratory result: error = (monitor result - hexokinase result)( hexokinase result The ADA Consensus Panel of 1986 recommended that results from monitors should fall within 15% of the target value set by the laboratory method: I 100 (monitor result - hexokinase result)( hexokinase result < 15 Table 3 lists the proportions of patient specimen results that exceeded this limit. It is evident that by this criterion all but a few monitors appeared to be in substantial error. Components of error in relation to the ADA guideline The relative contributions of imprecision and inaccuracy to the total error can be inferred by TABLE 3. Incidence ofsignificant error Rank Monitor Error (%). I YSI2300 t 0 2 Sensorex 6 3 SureStep 7 4 Accutrend Maxi 9 5 Esprit 15 6 Accutrend Alpha 16 7 Companion ExacTech 25 9 Glucometer Lynx Accutrend Mini Refiolux Betachek Advantage BM-I Glucometer One Touch Profile Dia-Screen Glucocard II 76 10" 13" DB Bias(%) 19't, 17 B FIGURE I. Bias and imprecision of monitors. The statistics on imprecision and on bias are from Tables 1, 2 and 4. The monitors are as ranked in Table 3: 1 = YSI 2300 (the dedicated laboratory glucose analyser); 2=Sensorex; 3=J&J SureStep; 4=BM Accutrend Maxi; 5 = Bayer Esprit; 6 = BM Accutrend Alpha; 7= Medisense Companion 2; 8= Medisense ExacTech; 9=Bayer Glucometer 2; 10=NDP Lynx; ll=bm Accutrend Mini; 12=BM Reflolux; 13=NDP Betachek; 14=BM Advantage; 15=BM-144; 16=Bayer Glucometer 3; 17=J&J One Touch Profile; 18=Dia Screen; 19 = KDK Glucocard II (see text for manufacturers' details). The circles indicate the upper bounds on bias and imprecision that are consistent with 95% of results falling within 15% ofthe target. Ann Clin Biochem 1999: 36
5 76 Johnson and Baker TABLE 4. Bias of monitors Value for Value for hexokinase monitor Difference Monitor (mmol/l)" (mmol/l)" (mmol/l) Error (%)1 pi SureStep < Esprit < Glucocard II < One Touch Profile < Sensorex! Maxi! YSI23()() < ExacTechi Betachek! Mini! Lynx! Reflolux! Glucometer 2! Companion 2! < Alpha' < BM-I < Advantage! < Glucometer < Dia-Screenl < *Mean of patients' specimen data. t[(value for monitor)-(value for hexokinase)]/(value for hexokinase) x 100%, sign ignored. IProbability that the Monitor and Hexokinase results are the same (by paired r-test), 'Results from Reference 6. TABLE 5. Predicted reading ofmonitors at defined glucose concentrations 95% confidence interval" At 4mmol/L At 17mmol/L Monitor Lower Upper Lower Upper YSI One Touch Profile H SureStep Accutrend Alpha Glucocard II Companion Esprit Sensorex Accutrend Maxi Advantage Reflolux Accutrend Mini Lynx BM-I Betachek ExacTech Glucometer Glucometer Dia-Screen *Expected deviations were calculated as bias± 2Sy.x at the selected concentration. "The YSI 2300 instrument was the dedicated laboratory glucose analyser. Ann Clin Biochem 1999: 36
6 Analytical error of home glucose monitors 77 plotting them as shown in Fig. 1. The imprecision for each monitor is the CV from regression (see Tables 1 and 2), and the bias is from Table 4. The monitors are numbered according to their ranking for significant error (see Table 3). Also shown are the allowable limits if results are to be within 15% of the target value on 95% of occasions, corresponding to 5% error in Table 3. Consistent with the information in Table 3, the YSI 2300 instrument met the 5% error limit and is included in the target area, whereas all others, apart from the SureStep, fell outside the target area. By applying a "i test to the data in Table 3, it was found that the Sensorex (6% error), SureStep (7%) and Accutrend Maxi (9%) did not differ significantly from the 5% error limit. It is evident from Fig. 1 that several of the monitors could have fallen within the allowable limits if calibrated differently, i.e., with less positive bias at the same degree of imprecision. Possible impact of total error on routine monitoring The combined effects of bias and imprecision on routine testing can be gauged from the predicted range of readings calculated as bias ±2Sy.x. The results shown in Table 5 are for a low and high concentration of glucose with the monitors ranked according to the extent of the greater (upper or lower) deviation at 4mmol/L. These values indicate that for a target concentration of 4 mrnol/l, the One Touch Profile can be expected to give a result (in about 95% of cases) of mmol/L. At the other extremity of performance, the Dia-Screen can be expected to give a result of mmol/l, While the extent of error at this low concentration may be overestimated by use of a constant estimate of error (standard deviation), difference plots" (not shown) did not suggest that a proportional estimate of error (CV) was more appropriate. DISCUSSION Meaning of the ADA guidelines Although the ADA guidelines'< ideally could be interpreted directly as analytical goals, the meaning of these recommendations in terms of the accepted analytical criteria of imprecision, inaccuracy and total error is unclear. The recommendation on variability being less than 10% might be interpreted as a CV of less than 10%. If this were the case, eight of 18 monitors in this study (Tables 1 and 2) would show acceptable performance. On the other hand, some authors have suggested that the recommendations imply an imprecision as a CV of less than 4% with no more than 5% bias,? targets approaching the performance of sophisticated laboratory analysers. Such performance is clearly beyond the capability of all the monitors evaluated in this study. Even these strict limits fall short when considering that they must embody the notion of '100% of the time'.' Similarly, while a majority of results might fall within 15% ofthe target value, it is unrealistic to expect every result to achieve this standard. We have proposed an alternative interpretation of the ADA guidelines by asking what degrees of imprecision and bias are consistent with 95% of values differing from the reference value by no more than 15%. This approach sets no explicit target for imprecision and bias in that the same total error can be achieved by various combinations of these parameters, with lesser precision being compensated by greater accuracy, and conversely (Fig. 1). However, upper limits are definable: with no imprecision, bias can be no higher than 15%, and with no bias, imprecision as CV can be no greater than 7 7%, very close to the CV of 7% recommended for these devices following interviews of patients and physicians. 10 Performance of the monitors against the ADA guideline While no monitor clearly fell within our interpretation of the guideline, three (Sensorex, SureStep and Accutrend Maxi) did not differ significantly from it and others (Esprit, Accutrend Alpha, Advantage, One Touch Profile and Glucocard II) were of suitably low imprecision, suffering only because of a high bias against our whole-blood glucose assay (see Fig. 1). We have discussed previously" how the adoption by manufacturers of a common basis for calibration and reporting whether as glucose in whole blood, as determined here, or as glucose in plasma would simplify both the interpretation of results and decisions on patient management. Such an approach is straightforward to implement and might resolve much of the variation in bias. Reliability of the results Imprecision in the comparison method does not affect this conclusion, as may be appreciated from the imprecision statistics obtained with the YSI 2300 instrument: the aqueous control solutions giving CVs of 2 5% (at 2-4mmol/L) Ann Clin Biochem 1999: 36
7 78 Johnson and Baker and 1 8% (at 23 7 mmol/l) with the YSI (see Table 1) had CVs of 2 2 and 0 9%, respectively, with the hexokinase laboratory method." Assuming that the two methods of measurement are equally imprecise, the apparent CV of 2 1% achieved with capillary blood specimens on the YSI (see Table 1)will include an equal contribution from the laboratory method, resulting in an estimated CV of 1 4% for each. Taking this estimated imprecision of the laboratory method into account for the most precise monitor, the One Touch Profile, results in its CV being lowered from 5 2 to 5 0%. For less precise monitors, the decrement is progressively smaller so that imprecision of the ExacTech and Dia-Screen (CV of 19 0 and 22-8%, respectively) is unaffected. Improved performance with amperometric devices As a group, amperometric devices offered a decisive advantage: three of the six had a CV of less than 7 7%, our derived upper limit for imprecision, and five of the six were below 10% (see Table 2). Of the colorimetric devices in our study, only three of the twelve offered comparable performance, while, as might be expected, most of the other non-wipe systems (Accutrends) tended to be more precise than the earlier systems that required wiping, the Dia Screen being an exception in this respect. This improvement in precision follows acceptance of the ADA recommendation that 'blood glucose monitors that are easier to use and less dependent on user skill should be developed';' The implication for those monitors with poor precision in this study is that they are insufficiently robust for routine use. The need for reconsideration of the ADA guideline It is clear that only the most modem meters can achieve the ADA recommendation of a decade ago and this only following a consensus among manufacturers on how meters should be calibrated and whether they should report whole blood or plasma glucose values. Whether the goal itself is unrealistic remains in doubt. Comparison with the acceptable performance criteria of the Royal College of Pathologists of Australasia-Australasian Association of Clinical Biochemists Quality Assurance Programme for glucose analysis in the laboratory is helpful in answering this question: this Programme accepts results within 1mmol/L of the target value up to a concentration of 10mmol/L and within 10% for target concentrations above 10mmol/L. Against the ADA recommendation of an error of less than 15% at all concentrations, the laboratory criterion is the more stringent for target concentrations of 6 7 mmol/l and above, whereas below 6 7mmol/L the situation is reversed. Although diabetic patients are understandably concerned about bypoglycaemia," it is clearly inappropriate to recommend a performance standard for home monitors that is more demanding than that for laboratory analysers. As noted above, the guideline also fails to allow for the natural dispersion of values in apparently stipulating that all monitor results should fall within 15% of the reference. We have suggested that 95% should reach this standard, but whether such a proportion satisfies the intention of the ADA requires clarification. This tolerance needs to be known in order to set the allowable limits on imprecision as illustrated in Fig. 1. CONCLUSION In conclusion, the present study shows that modem meters, and especially those ofampero metric design, are capable ofperforming close to the standard implied by the ADA's recommendations. However, there are two main reasons underlying their apparent failure here which may also affect evaluation of their performance in future: firstly, there is a lack of consensus among manufacturers on calibration and reporting of monitor results; and secondly, the ADA recommendation that results from meters should be within 15% of the laboratory result is without regard either to the concentration of glucose or to the imprecision of measurement. Both of these issues require urgent attention. Acknowledgements We wish to express our thanks to Pharmac for financial support, to Boehringer-Mannheim (NZ) for providing autolancets, to Medica Pacifica for making the YSI glucose analyser available to us; to the staff and patients of the Auckland Diabetes Centre and of the Diabetes Clinic of North Shore Hospital who made the study possible; and to Suzanne Boric, Suzanne Grapengiesser, Sarah Sargon and Barbara Smith for expert technical assistance. REFERENCES American Diabetes Association: Consensus statement on self-monitoring of blood glucose. Diabetes Care 1987; 10: 95-9 Ann cu«biochem 1999: 36
8 Analytical error ofhome glucose monitors 79 2 American Diabetes Association: Consensus statement on self-monitoring of blood glucose. Diabetes Care 1994; 17: The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: Koschinsky T, Dannehl K, Gries FA. New approach to technical and clinical evaluation of devices for self-monitoring of blood glucose. Diabetes Care 1988; 11: Havlin CE, Parvin CA, Cryer PE. The accuracy of blood glucose monitoring devices. Clin Diabetes 1991; 9: Johnson RN, Baker JR. Accuracy of devices used for self-monitoring of blood glucose. Ann Clin Biochem 1998; 35: Westgard JO, Hunt MR. Use and interpretation of common statistical tests in method-comparison studies. Clin Chem 1973; 19: Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: Rainey PM, Jatlow P. Monitoring blood glucose meters. Am J cu«pathol 1995; 103: Weiss SL, Cembrowski GS, Mazze RS. Patient and physician analytic goals for self-monitoring blood glucose instruments. Am J Clin Pathol 1994;102:611-5 Accepted/or publication 23 June 1998 Ann cu«biochem 1999: 36
System accuracy evaluation of FORA Test N Go Blood Glucose Monitoring System versus YSI 2300 STAT Plus glucose analyzer following ISO 15197:2013
System accuracy evaluation of FORA Test N Go Blood Glucose Monitoring System versus YSI 2300 STAT Plus glucose analyzer following ISO 15197:2013 Abstract Objective: The goal of the study was to assess
More informationSystem accuracy evaluation of FORA Test N Go Blood Glucose Monitoring System versus YSI 2300 STAT Plus glucose analyzer following ISO 15197:2013
System Accuracy Evaluation of Project number: Fora092614-01 System accuracy evaluation of Blood Glucose Monitoring System versus YSI 2300 STAT Plus glucose analyzer following ISO 15197:2013 Date: 13 th
More informationEquivalent Accuracy Evaluation of FORA Premium V10 Blood Glucose Monitoring System as Compared to Fora V30 Blood Glucose Monitoring System
Equivalent Accuracy Evaluation of FORA Premium V10 Blood Glucose Monitoring System as Compared to Fora V30 Blood Glucose Monitoring System Abstract Objective: Both Fora Premium V10 and V30 blood glucose
More informationFreeStyle Lite A Blood Glucose Meter That Requires No Coding
Journal of Diabetes Science and Technology Volume 2, Issue 4, July 2008 Diabetes Technology Society SYMPOSIUM Shridhara, Ph.D. Abstract Background: Abbott Diabetes Care introduced the FreeStyle Lite blood
More informationValidity and Reliability of a Glucometer Against Industry Reference Standards
514315DSTXXX10.1177/1932296813514315Journal of Diabetes Science and TechnologySalacinski et al research-article2014 Original Article Validity and Reliability of a Glucometer Against Industry Reference
More informationGlucoMen LX PLUS blood glucose and blood ketone meter. Accuracy Evaluation to New ISO 15197:2013, with Technical and Specification Data
GlucoMen LX PLUS: Accuracy Evaluations to ISO 15197:2013 with Technical and Specification Data GlucoMen LX PLUS blood glucose and blood ketone meter Accuracy Evaluation to New ISO 15197:2013, with Technical
More informationClinical Accuracy and User Performance of the TRUE METRIX AIR Blood Glucose Monitoring System
Clinical Accuracy and User Performance of the TRUE METRIX AIR Blood Glucose Monitoring System Summary Objectives: To demonstrate that the TRUE METRIX AIR Blood Glucose Monitoring System, from Trividia
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k103542 B. Purpose for Submission: Alternative blood glucose test strips for use with LifeScan OneTouch
More informationBern Harrison, B.A., Cheryl Leazenby, B.S., and Solveig Halldorsdottir, Ph.D.
Journal of Diabetes Science and Technology Volume 5, Issue 4, July 2011 Diabetes Technology Society TECHNOLOGY REPORTS Accuracy of the CONTOUR Blood Glucose Monitoring System Bern, B.A., Cheryl Leazenby,
More informationAina Blood Monitoring System
Aina Blood Monitoring System Analytical Performance Summary The Aina Blood Monitoring System is a high quality and versatile multi-parameter diagnostic platform that is CE-marked and approved for sale
More informationReport. Evaluation of system accuracy of the blood glucose monitoring system VivaChek Ino according to DIN EN ISO 15197: 2013
Institute of Diabetes Gerhardt Katsch Karlsburg (IDK) Report Evaluation of system accuracy of the blood glucose monitoring system VivaChek Ino according to DIN EN ISO 15197: 2013 Sponsor: The study was
More informationMETHOD VALIDATION: WHY, HOW AND WHEN?
METHOD VALIDATION: WHY, HOW AND WHEN? Linear-Data Plotter a,b s y/x,r Regression Statistics mean SD,CV Distribution Statistics Comparison Plot Histogram Plot SD Calculator Bias SD Diff t Paired t-test
More informationEvaluation of Accuracy and User Performance of the TRUE METRIX Self-Monitoring Blood Glucose System
Evaluation of Accuracy and User Performance of the TRUE METRIX Self-Monitoring Blood Glucose System Summary Objectives: To demonstrate that the TRUE METRIX Self-Monitoring Blood Glucose System*, from Trividia
More informationEvaluation of Accuracy and User Performance of the TRUE METRIX Blood Glucose Monitoring System
Evaluation of Accuracy and User Performance of the TRUE METRIX Blood Glucose Monitoring System Summary Objectives: To demonstrate that the TRUE METRIX Blood Glucose Monitoring System, from Trividia Health,
More informationWhite Paper, Evaluation of WaveSense JAZZ Blood Glucose Monitoring System Analytical Performance to EN ISO 15197:2015 Standard
White Paper, Evaluation of WaveSense JAZZ Blood Glucose Monitoring System Analytical Performance to EN ISO 15197:2015 Standard 7500-10032 Rev F Table of Contents Executive Summary 3 Changes introduced
More informationGlucose Analytical Comparability Evaluation of the YSI 2300 STAT Plus and YSI 2900D Biochemistry Analyzers
Glucose Analytical Comparability Evaluation of the YSI 2300 STAT Plus and YSI 2900D iochemistry Analyzers Life Sciences Data for Life. TM YSI Life Sciences White Paper 91 Authors: Kevin Schlueter, PhD,
More informationMQ Comparison of glucometers using heparin whole blood
MQ 2014-1 Comparison of glucometers using heparin whole blood Note: The instrument comparison is structured as a survey. This is a sample test, not a complete evaluation. Introduction Glucose self-testing
More informationQuality Control of Self-Monitoring of Blood Glucose: Why and How?
Journal of Diabetes Science and Technology Volume 1, Issue 2, March 2007 Diabetes Technology Society SYMPOSIUM Quality Control of Self-Monitoring of Blood Glucose: Why and How? Bogdan, M.D., Ph.D. and
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number: k100322 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE B. Purpose for Submission: Clearance of a new device C. Measurand: Whole
More informationPolymer Technology Systems, Inc. CardioChek PA Comparison Study
Polymer Technology Systems, Inc. CardioChek PA Comparison Study Evaluation Protocol: Accuracy Precision Clinical Correlation PTS Panels Lipid Panel Test Strips For Use in Comparisons to a Reference Laboratory
More informationForum for Collaborative HIV Research External Validation of CD4 and Viral Load Assays Paris, France June 29, 2007
Forum for Collaborative HIV Research External Validation of CD4 and Viral Load Assays Paris, France June 29, 2007 Thomas J. Spira, M.D. International Laboratory Branch Global AIDS Program Centers for Disease
More informationTechnical Evaluation of Five Glucose Meters With Data Management Capabilities
Clinical Chemistry / LABORATORY EVALUATION OF GLUCOSE METERS Technical Evaluation of Five Glucose Meters With Data Management Capabilities Jeffrey]. Chance, PhD, Dai J. Li,MD, PhD, Kerrie A. Jones, MS,
More informationWeek 17 and 21 Comparing two assays and Measurement of Uncertainty Explain tools used to compare the performance of two assays, including
Week 17 and 21 Comparing two assays and Measurement of Uncertainty 2.4.1.4. Explain tools used to compare the performance of two assays, including 2.4.1.4.1. Linear regression 2.4.1.4.2. Bland-Altman plots
More informationQuality Specifications for POCT
Quality Specifications for POCT the patient journey perspective Christopher P Price Department of Clinical Biochemistry, University of Oxford, Oxford, UK Quality Specifications fit-for-purpose QUALITY
More informationPatricia C. Fallest-Strobl, 1 Elin Olafsdottir, 2 Donald A. Wiebe, 1 and James O. Westgard 1 * Lipoproteins
Clinical Chemistry 43:11 2164 2168 (1997) Lipids and Lipoproteins Comparison of NCEP performance specifications for triglycerides, HDL-, and LDL-cholesterol with operating specifications based on NCEP
More informationA meter designed for glucose self-measurement manufactured by LifeScan, Johnson & Johnson. Report from an evaluation organised by SKUP
SKUP Scandinavian evaluation of laboratory equipment for primary health care ONETOUCH Ultra A meter designed for glucose self-measurement manufactured by LifeScan, Johnson & Johnson Report from an evaluation
More informationEvolution of Analytical Performance in Portable Glucose Meters in the Last Decade
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Evolution of Analytical Performance in Portable Glucose Meters in the Last Decade PHILIP BÖHME, MD MICHELE FLORIOT, MD MARIE-AUDE SIRVEAUX,
More informationMQ Comparison of glucometers using whole blood
MQ 2017-1 Comparison of glucometers using whole blood Note: The instrument comparison is structured as a survey. This is a sample test, not a complete evaluation. Introduction Glucose self-testing devices
More informationRelationship between glucose meter error and glycemic control efficacy
Relationship between glucose meter error and glycemic control efficacy Brad S. Karon, M.D., Ph.D. Professor of Laboratory Medicine and Pathology Department of Laboratory Medicine and Pathology Mayo Clinic
More informationINTERNAL QUALITY CONTROL ( Q I C) QC)
EXTERNAL QUALITY ASSESSMENT PROGRAM (EQAP) BIOCHEMISTRY DEPARTMENT R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty TWO COMPLEMENTARY COMPONENETS OF TQM ARE Internal Quality Control (IQC)
More informationMQ Comparison of glucometers using whole blood
MQ 2018-2 Comparison of glucometers using whole blood Note: The instrument comparison is structured as a survey. This is a sample test, not a complete evaluation. Introduction Glucose self-testing devices
More informationEvaluation Report: Eurolyser CRP test (ST0100 and ST0102) on. CUBE analyser (CA0100)
Evaluation Report: Eurolyser CRP test (ST0100 and ST0102) on CUBE analyser (CA0100) Location Location: Eurolyser Diagnostica GmbH Operators: Simone Wieser; Franz Helminger; Michael Gruber Date: July-November
More informationReference Material Institute for Clinical Chemistry Standards (ReCCS)
Certified Reference Material for Measurement of Glucose, Creatinine, Uric Acid and Urea-N in Human Serum JCCRM Certificate of Analysis Intended use This Certified Reference Material CRM is intended primarily
More informationSUMMARY... 2 PLANNING OF THE EVALUATION... 4 ANALYTICAL QUALITY SPECIFICATIONS... 5
USER-EVALUATION ASCENSIA CONTOUR Blood Glucose Meter System Table of contents SUMMARY... 2 PLANNING OF THE EVALUATION... 4 ANALYTICAL QUALITY SPECIFICATIONS... 5 MATERIALS AND METHODS... 6 ASCENSIA CONTOUR...
More informationAccuracy and Precision Performance of the Accu-Chek Mobile System. Introduction. Method
Accuracy and Precision Performance of the Accu-Chek Mobile System I. ACCURACY The accuracy of the system was assessed according to ISO 15197. Introduction The purpose of this study was to determine the
More informationNICO /14 Nipro Diagnostics, Inc.
Clinical Performance of the TRUEresult twist Blood Glucose Monitoring System () Using ISO 15197:13 Criteria for Accuracy Utilizing GDH-FAD Enzyme NICO-8 1/1 Nipro Diagnostics, Inc. NICO_8_mmol.indd CLINICAL
More informationAnalysis of Hemoglobin A1c from Dried Blood Spot Samples with the Tina-quant II Immunoturbidimetric Method
Journal of Diabetes Science and Technology Volume 4, Issue 2, March 2010 Diabetes Technology Society SYMPOSIUM Analysis of Hemoglobin A1c from Dried Blood Spot Samples with the Tina-quant II Immunoturbidimetric
More information1 PROTOCOL. Comparison Study Summary. Springs Memorial Hospital. Springs Memorial Hospital 800 W. Meeting St. Lancaster, SC (803)
Comparison Study Summary Springs Memorial Hospital 800 W. Meeting St. Lancaster, SC 29720 (803) 286-1480 February 10, 2016 1 PROTOCOL This evaluation was conducted on February 10, 2016 at Springs Memorial
More informationA model for managing and monitoring the quality of glucometers used in a high-volume clinical setting
Original papers A model for managing and monitoring the quality of glucometers used in a high-volume clinical setting Güzin Aykal*, Ayşenur Yegin, Özgür Tekeli, Necat Yilmaz Central Laboratories, Antalya
More informationMethod Precision and Frequent Causes of Errors Observed in Point-of-Care Glucose Testing. A Proficiency Testing Program Perspective
Method Precision and Frequent Causes of Errors Observed in Point-of-Care Testing A Proficiency Testing Program Perspective Berna Aslan, MD, 1 Julia Stemp, ART, 1 Paul Yip, PhD, 2 and Jane Gun-Munro, MLT,
More informationFarouk AL Quadan lecture 3 Implentation of
How to implement a program? Establish written policies and procedures Assign responsibility for monitoring and reviewing Train staff Obtain control materials Collect data Set target values (mean, SD) Establish
More informationTheraSense FreeStyle blood glucose meter
May 2002 Evaluation Report MDA 02049 TheraSense FreeStyle blood glucose meter Crown Copyright 60 WHAT YOU CAN EXPECT FROM MDA EVALUATION REPORTS The Device Evaluation Service (DES) aims to provide independent
More informationMethod Comparison Report Semi-Annual 1/5/2018
Method Comparison Report Semi-Annual 1/5/2018 Prepared for Carl Commissioner Regularatory Commission 123 Commission Drive Anytown, XX, 12345 Prepared by Dr. Mark Mainstay Clinical Laboratory Kennett Community
More informationGD50. Simple. Accurate. Reliable. Test Simply. Live Better. All FORA Diamond Series Blood Glucose Monitoring Systems use FORA Diamond Test Strips.
GD50 Higher Measuring Accuracy Simple. Accurate. Reliable. Test Simply. Live Better. All FORA Diamond Series Blood Glucose Monitoring Systems use FORA Diamond Test Strips. GD50 Simple. Accurate. Reliable.
More informationSmart & Simple Mobile Solutions.
Higher Measuring Accuracy Smart & Simple Mobile Solutions. Test Simply. Live Better. FORA Diamond lets you connect all your Bluetooth devices. *Also available with a Micro USB. ifora Diabetes Manager All
More informationGB/T Translated English of Chinese Standard: GB/T
Translated English of Chinese Standard: GB/T 19634-2005 www.chinesestandard.net Sales@ChineseStandard.net GB ICS 11.100 C 44 National Standard of the People s Republic of China GB/T 19634-2005 In vitro
More information(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)
cobas b system - performance evaluation Study report from a multicenter evaluation of the new cobas b system for the measurement of HbAc and lipid panel Introduction The new cobas b system provides a point-of-care
More informationA meter designed for glucose self-measurement manufactured by Roche Diagnostics. Report from an evaluation organised by SKUP
SKUP Scandinavian evaluation of laboratory equipment for primary health care ACCU-CHEK Compact Plus A meter designed for glucose self-measurement manufactured by Roche Diagnostics Report from an evaluation
More informationSCIEX Vitamin D 200M Assay for the Topaz System
The First FDA-Cleared LC-MS/MS Assay for Vitamin D SCIEX Vitamin D 200M Assay for the Topaz System The first FDA-cleared LC-MS/MS assay for Vitamin D Vitamin D is an important building block for human
More informationEvaluation of the Analytical Performance of the Coulometry-Based Optium Omega Blood Glucose Meter
Journal of Diabetes Science and Technology Volume 5, Issue 6, November 2011 Diabetes Technology Society TECHNOLOGY REPORT Evaluation of the Analytical Performance of the Coulometry-Based Optium Omega Blood
More informationClinical Chemistry / INTENSIVE INSULIN THERAPY AND GLUCOSE VALUES
Clinical Chemistry / INTENSIVE INSULIN THERAPY AND GLUCOSE VALUES Accuracy of Roche Accu-Chek Inform Whole Blood Capillary, Arterial, and Venous Glucose Values in Patients Receiving Intensive Intravenous
More informationVALIDATION OF CONTINUOUS GLUCOSE MONITORING IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS - A PROSPECTIVE COHORT STUDY
Diabetes Care Publish Ahead of Print, published online March 11, 2009 Validation of CGM in Children with CF VALIDATION OF CONTINUOUS GLUCOSE MONITORING IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS
More informationAccuracy of Portable Blood Glucose Monitoring
CLINICAL CHEMISTRY Accuracy of Portable Blood Glucose Monitoring Effect of Glucose Level and Prandial State DINO A. VALLERA, M.D., MICHAEL G. BISSELL, M.D., PH.D., M.P.H., AND WILLIAM BARRON, M.D. Glucose
More informationPerformance of three portable blood glucose monitoring devices used in a veterinary application
Performance of three portable blood glucose monitoring devices used in a veterinary application Prepared by Michael I. Lindinger, PhD, Vice-President of Research, The Nutraceutical Alliance, Campbellville,
More informationAssessing Agreement Between Methods Of Clinical Measurement
University of York Department of Health Sciences Measuring Health and Disease Assessing Agreement Between Methods Of Clinical Measurement Based on Bland JM, Altman DG. (1986). Statistical methods for assessing
More information" EXTERNAL QUALITY EVALUATION PROGRAM FOR POCT GLUCOSE TESTING years of experience
Commissie voor Klinische Biologie Commission de Biologie Clinique " EXTERNAL QUALITY EVALUATION PROGRAM FOR POCT GLUCOSE TESTING 8 3 years of experience CM Van Campenhout JC Libeer WIV/ISP/IPH Clinical
More informationEVALUATION OF THE PERFORMANCE OF THE TRUETRACK BLOOD GLUCOSE MONITORING SYSTEM USING THE ISO 15197:2003 ACCURACY AND USER EVALUATION REQUIREMENTS
EVALUATION OF THE PERFORMANCE OF THE TRUETRACK BLOOD GLUCOSE MONITORING SYSTEM USING THE ISO 15197:23 ACCURACY AND USER EVALUATION REQUIREMENTS Douglas E. Bell, PhD Teri A. Sasse, RN, MS BACKGROUND: The
More informationClinical Evaluation for. Embrace No Code Blood Glucose Monitoring System
Embrace No Code Report Clinical Evaluation for Embrace No Code Blood Glucose Monitoring System Applicant: Apex Biotechnology Corp. Test Date: 2007/8/28~2007/9/21 Clinical Site: SCHMIDT Group Practice Clinic
More informationThe analytical phase
The analytical phase Result interpretation Test request Result Sampling Black box: the lab ANALYTICAL PHASE The CASE Uncle Pete, 67 years old Marked abdominal pain 8 pm, ED Acute abdomen? Assessment (+
More informationTitle: Abbott Optium Xceed Glucose Meter Effective date: 16/05/2011. Summary of Significant Changes at this Revision. SOP updated.
COPY Summary of Significant Changes at this Revision SOP updated Purpose and Scope Items Required 1. The Abbott Optium Xceed meter is a battery-powered device designed for the measurement of blood glucose
More informationUltra Blue. Test Strips UNISTRIP. Charlotte, NC V2-10/25/2018 TECHNOLOGIES,LLC
VS UNISTRIP TECHNOLOGIES,LLC Charlotte, NC 28269 1-866-889-6229 V2-10/25/2018 UniStrip Generic Blood Glucose VS OneTouch Ultra Blue 1. Purpose This study is intended to evaluate the difference in values
More informationAn update on the analysis of agreement for orthodontic indices
European Journal of Orthodontics 27 (2005) 286 291 doi:10.1093/ejo/cjh078 The Author 2005. Published by Oxford University Press on behalf of the European Orthodontics Society. All rights reserved. For
More informationNon-invasive blood glucose measurement by near infrared spectroscopy: Machine drift, time drift and physiological effect
Spectroscopy 24 (2010) 629 639 629 DOI 10.3233/SPE-2010-0485 IOS Press Non-invasive blood glucose measurement by near infrared spectroscopy: Machine drift, time drift and physiological effect Simon C.H.
More informationState of the Art of HbA1c Measurement
State of the Art of HbA1c Measurement XXI Congreso Latinoamericano de Patologia Clinica Y XLII Congreso Mexicano de Patologia Clinica, Cancun October 2012 Randie R. Little, Ph.D. NGSP Network Laboratory
More informationEvaluation of VACUETTE Urine CCM tube for Clinical Chemistry
Evaluation of VACUETTE Urine CCM tube for Clinical Chemistry Background The VACUETTE Urine CCM tube is for the collection, transport and storage of urine samples for urine culture and urinalysis in the
More informationEvaluation Report. Eurolyser Lactate test kit (VT0220, VT0221) on solo analysers
Evaluation Report Eurolyser Lactate test kit (VT0220, VT0221) on solo analysers Location: Operators: Eurolyser Diagnostica GmbH Simone Wieser, Bettina Schönauer, Dr. Jürgen Berlanda Report created on 17
More informationMETHOD VALIDATION CASE
METHOD VALIDATION CASE METHOD VALIDATION PROTOCOL CLIA Regulation 493.1253 (2) 1.Accuracy (closeness to true/comparative method) 2.Precision (reproducibility) 3.Reference Interval 4.Reportable range (linearity,
More informationIn Vitro Diagnostic Glucose Test System
CDRH Final Guidance 2-Page Cover Sheet Guidance for Industry In Vitro Diagnostic Glucose Test System Document issued on: July 6, 1998 U.S. Department Of Health and Human Services Food and Drug Administration
More informationComparison of Three Whole Blood Creatinine Methods for Estimation of Glomerular Filtration Rate Before Radiographic Contrast Administration
Clinical Chemistry / Whole Blood Creatinine for egfr Comparison of Three Whole Blood Creatinine Methods for Estimation of Glomerular Filtration Rate Before Radiographic Contrast Administration Nichole
More informationSelecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan
729488DSTXXX10.1177/1932296817729488Journal of Diabetes Science and TechnologyWestgard et al research-article2017 Original Article Selecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan Journal
More informationDetermination of hemoglobin is one of the most commonly
ORIGINAL ARTICLE Multiple-Site Analytic Evaluation of a New Portable Analyzer, HemoCue Hb 201+, for Point-of-Care Testing Sten-Erik Bäck, PhD,* Carl G. M. Magnusson, PhD, Lena K. Norlund, MD, PhD, Henning
More informationEVALUATING THE UNCERTAINTY OF MEASUREMENT ON BLOOD'S GLUCOSE LEVEL
BIOMEDICAL ENGINEERING- APPLICATIONS, BASIS & COMMUNICATIONS EVALUATING THE UNCERTAINTY OF MEASUREMENT ON BLOOD'S GLUCOSE LEVEL 91 HUNG-CHUN HUANG 1,2, CHIA-HUNG CHIEN 1,2, CHENG-YI WANG 1, FOK-CHING CHONG
More informationA validation study of after reconstitution stability of diabetes: level 1 and diabetes level 2 controls
A validation study of after reconstitution stability of diabetes: level 1 and diabetes level 2 controls Shyamali Pal R B Diagnostic Private Limited, Lake Town, Kolkata, India INFO ABSTRACT Corresponding
More informationBias in clinical chemistry. Elvar Theodorsson EFLM and Linköping University
Bias in clinical chemistry Elvar Theodorsson EFLM and Linköping University Bias a controversial subject Different perspectives Reseachers Users Regulatory bodies Standardisation organisations Metrologists
More informationThe performance of Microdot Test Strips has been evaluated both in laboratory and in clinical tests.
Chemical Composition Each Microdot strip contains the enzyme glucose dehydrogenase (Bacillus Sp.) = 1 IU and other ingredients (mediator, NAD, lysing agents etc.) = 200 µg. Test Strips When blood is added
More informationComparison of Modified Jaffe s Kinetic Method and Enzymatic Method of Serum Creatinine Estimation for Precision, Linearity and Effect of Interferent
ORIGINAL ARTICLE Comparison of Modified Jaffe s Kinetic Method and Enzymatic Method Comparison of Modified Jaffe s Kinetic Method and Enzymatic Method of Serum Creatinine Estimation for Precision, Linearity
More informationApproval of Multiple Diabetes Management Products and Mesalazine proposals
8 June Approval of Multiple Diabetes Management Products and Mesalazine proposals PHARMAC is pleased to announce the approval of five agreements in relation to funding of blood glucose, blood glucose diagnostic
More informationAccuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips
Accuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips Sponsored by Arthur Roberts, MD of The Living Heart Foundation The Living Heart
More informationLIPASE liquicolor. Design Verification. Multipurpose Reagent
Design Verification LIPASE liquicolor Multipurpose Reagent CONTENTS 1 Introduction... 2 2 Imprecision... 2 3 Linearity and Detection Limit... 2 3.1 Linearity... 2 3.2 Detection Limit... 3 4 Recovery of
More informationPerformance Evaluation of B. Braun Omnitest 5 Blood Glucose Monitoring System for Self-Monitoring of Blood Glucose
ORIGINL RTILE https://doi.org/10.15263/jlmqa.2016.38.4.234 Performance Evaluation of. raun Omnitest 5 lood Glucose Monitoring System for Self-Monitoring of lood Glucose Kyungso Jeon 1 and Miseon Shin 2
More informationThe Integrated Cardiovascular Clinical Network CHSA
The Integrated Cardiovascular Clinical Network CHSA Roche cobas b 101 HbA1c and Lipids Evaluation July 2013 Introduction Cardiovascular disease (CVD) is the leading cause of mortality in Australia, accounting
More informationSandra Božičević dipl. ing. med. biochem, Marijana Vučić Lovrenčić, PhD Vuk Vrhovac University Clinic, Zagreb, Croatia
16. PRE-ANALYTICAL, ANALYTICAL AND POST-ANALYTICAL FACTORS INFLU- ENCING SPECIFIC TESTS FOR DIAGNOSIS AND MONITORING OF DM-National network in quality assessment Prof. Dubravka Juretić, Ph.D. University
More informationBLOOD GLUCOSE METERS ACCURACY REQUIREMENTS
BLOOD GLUCOSE METERS ACCURACY REQUIREMENTS International Standard ISO 15197:2013 (Second Edition 15/05/2013) In vitro diagnostic test systems Requirements for blood-glucose monitoring systems for self-testing
More informationUSING THE ACCESS AMH ASSAY IN YOUR LABORATORY
INFORMATION BULLETIN USING THE ACCESS AMH ASSAY IN YOUR LABORATORY ///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
More informationSummary of Significant Changes at this Revision. Items Required
Update Approver/checker Summary of Significant Changes at this Revision Purpose and Scope Items Required 1. The Abbott FreeStyle Optium meter is a battery-powered device designed for the measurement of
More information1. PROTOCOL. Comparison Study Summary. Tuality Healthcare 324 SE 9 th Ave. Suite E Hillsboro, OR July 30, 2014
Comparison Study Summary Tuality Healthcare 324 SE 9 th Ave. Suite E Hillsboro, OR 97123 July 30, 2014 1. PROTOCOL This study was conducted on July 24 th, 2014 at Tuality Healthcare, Hillsboro, OR. The
More informationClinical Performance of the TRUE2go Blood Glucose Monitoring System Exceeds Minimum Criteria for Accuracy Using ISO 15197:2013
linical Performance of the TRUE2go lood Glucose Monitoring System Exceeds Minimum riteria for Accuracy Using ISO 197:213 LINIAL STUY SUMMARY EVALUATION OJETIVES This clinical evaluation: 1. Evaluates the
More informationOGCARE is a blood glucose monitoring device for checking glucose concentration in whole blood from fingertip pricking.
ITALIAN PRODUCT S E L F T E S T I N G Personal medical devices for metabolic disorders MONITORING and PREVENTION, taking advantage of reflectometric and electrochemical technologies. Blood glucose monitoring
More informationPerformance Guide. icheck Iodine The test kit to measure iodine in salt
Performance Guide icheck Iodine The test kit to measure iodine in salt Performance explained This Performance Guide is intended to explain the validity of our test kit icheck Iodine in a nutshell to facilitate
More informationPoint-of-Care glucose analysis in neonates using modified quinoprotein glucose dehydrogenase
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2013 Point-of-Care glucose analysis in neonates using modified quinoprotein glucose dehydrogenase Dennis J. Dietzen
More informationSummary of Significant Changes at this Revision
COPY Summary of Significant Changes at this Revision CR5890 Removal of Ketone guidelines - refer to Specialist Diabetes nurse (adult wards); Children's ward has their own protocol Remove all references
More informationSerum fructosamine and glycated haemoglobin
rchives of Disease in Childhood, 1986, 61, 113-117 Serum fructosamine and glycated haemoglobin measurements in diabetic control J HINDL, G M ROSTRON, S CLRK, ND J G1T Department of Biochemistry, Infirmary
More informationWhat Do Statistics Really Tell Us About the Quality of the Data from Self-monitoring of Blood Glucose?
What Do Statistics Really Tell Us bout the Quality of the Data from Self-monitoring of lood Glucose? R. F. Dedrick, W. K. Davis Michigan Diabetec Research and Training Center, University of Michigan Medical
More informationWhole blood glucose: what are we actually measuring?
Personal View Ann Clin Biochem 1995; 32: 1-8 Whole blood glucose: what are we actually measuring? Keith Wiener From the Department of Clinical Biochemistry, North Manchester General Hospital, Manchester
More informationPlasma Hemoglobin Determination: Two Manual Methods Compared. An Honors Thesis (HONRS 499) Anne M. Emerick. Sharlene Strahl. Beech Grove, Indiana
Plasma Hemoglobin Determination: Two Manual Methods Compared An Honors Thesis (HONRS 499) by Anne M. Emerick Sharlene Strahl St. Francis Hospital and Health Centers Beech Grove, Indiana Dr. Nancy Behforouz
More information3. System Accuracy Evaluation LUX Hgb test 1. Samples
3. System Accuracy Evaluation LUX Hgb test 1. Samples - Type of sample: Capillary Blood System accuracy evaluation was performed with 200 fresh capillary blood samples, each with sufficient volume to be
More informationISO INTERNATIONAL STANDARD
INTERNATIONAL STANDARD ISO 15197 First edition 2003-05-01 In vitro diagnostic test systems Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus Systèmes d'essais
More informationSKUP Scandinavian evaluation of laboratory equipment for primary health care
S K U P i n D e n m a r k, D E K S, R i g s h o s p i t a l e t - G l o s t r u p, DK- 2 6 0 0 G l o s t r u p, P h o n e + 4 5 3 8 6 3 4 4 0 0, w w w. s k u p. n u S K U P i n N o r w a y, N o k l u s,
More informationCommutability studies undertaken by the LNE : the case of lipid and lipoprotein testing. Vincent Delatour, PhD
Commutability studies undertaken by the LNE : the case of lipid and lipoprotein testing Vincent Delatour, PhD 1 Traceability in laboratory medicine : regulatory drivers Reform of medical biology in France
More information